Akums Drugs

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE09XN01023
NSEID: AKUMS
BSEID: 544222

INR

420.55

0.25 (0.06%)

BSENSE

Dec 05

BSE+NSE Vol: 24.76 k

{
  "main_header": {
    "sid": 10039335,
    "name": "Akums Drugs",
    "stock_name": "Akums Drugs",
    "full_name": "Akums Drugs & Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/akums-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "420.55",
    "chg": 0.25,
    "chgp": "0.06%",
    "dir": 1,
    "prev_price": "420.30",
    "mcapval": "6,619.20 Cr",
    "mcap": "Small Cap",
    "scripcode": "544222",
    "symbol": "AKUMS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE09XN01023",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "24.76 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/akums-drugs-10039335-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Akums Drugs Sees Revision in Market Evaluation Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/akums-drugs-downgraded-to-strong-sell-amid-weak-fundamentals-and-negative-financial-trends-3735195",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AkumsDrugs_mojoScore_3735195.png",
        "date": "2025-11-28 10:05:12",
        "description": "Akums Drugs has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and market positioning. This adjustment highlights evolving perspectives on the company’s financial health, valuation, technical outlook, and overall quality within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Akums Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-akums-drugs-fallingrising-3727211",
        "imagepath": "",
        "date": "2025-11-25 01:51:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>Akums Drugs has been on a losing streak, with the stock falling for five consecutive days and registering a weekly decline of 5.91%, significantly underperforming the Sensex, which remained almost flat with a marginal 0.06% gain over the same period. The stock is trading perilously close to its 52-week low, just 1.67% above the ₹407.4 mark, underscoring the persistent bearish sentiment among investors. Intraday activity further highlighted weakness, with the share price touching a low of ₹411.1, down 2.5% during the session, and a weighted average price indicating that most volume was transacted near these lower levels.</p>\n<p>Technically, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-..."
      },
      {
        "title": "How has been the historical performance of Akums Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-akums-drugs-3709302",
        "imagepath": "",
        "date": "2025-11-17 23:27:20",
        "description": "Answer:\nThe historical performance of Akums Drugs shows a significant recovery and growth in recent years, particularly in the fiscal year ending March 2025.\n\nBreakdown:\nIn the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, slightly down from 4,178.18 crore in March 2024 but up from 3,654.82 crore in March 2023. The total operating income mirrored the net sales at 4,118.16 crore for March 2025. The company's total expenditure decreased to 3,653.67 crore in March 2025 from 4,055.20 crore in March 2024, contributing to an operating profit (PBDIT) of 516.61 crore, a substantial increase from 157.01 crore in the previous year. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surged to 343.78 crore compared to just 0.79 crore in the prior year. The consolidated net profit also reflected t..."
      },
      {
        "title": "Akums Drugs Faces Financial Challenges Amid Declining Performance Metrics and Rising Costs",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/akums-drugs-pharmaceuticals-financial-trend-declines-from-flat-to-negative-amid-rising-costs-3701333",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AkumsDrugsPharm_fintrenddot_3701333.png",
        "date": "2025-11-14 11:03:32",
        "description": "Akums Drugs & Pharmaceuticals has faced a decline in financial performance for the quarter ending September 2025, despite reporting a higher profit after tax for the nine-month period. Key indicators show rising interest expenses and a significant drop in quarterly PAT, raising concerns about operational efficiency and financial sustainability."
      },
      {
        "title": "Akums Drugs Q2 FY26: Profit Plunges 37% as Margins Compress Under Rising Costs",
        "link": "https://www.marketsmojo.com/news/result-analysis/akums-drugs-q2-fy26-profit-plunges-37-as-margins-compress-under-rising-costs-3715583",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AkumsDrugsPharm_quaterlyResult_3715583.png",
        "date": "2025-11-14 09:46:28",
        "description": "Akums Drugs & Pharmaceuticals Ltd., one of India's leading pharmaceutical contract development and manufacturing organisations, reported a disappointing second quarter for FY2026, with consolidated net profit declining 37.46% year-on-year to ₹40.78 crores from ₹65.21 crores in Q2 FY25. The quarter-on-quarter performance was equally concerning, with profits falling 35.76% from ₹63.48 crores in Q1 FY26. The sharp contraction in profitability comes despite relatively stable revenue, raising questions about operational efficiency and cost management at the ₹6,635 crore market capitalisation company."
      },
      {
        "title": "How has been the historical performance of Akums Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-akums-drugs-3699859",
        "imagepath": "",
        "date": "2025-11-13 23:53:16",
        "description": "Answer:\nThe historical performance of Akums Drugs shows significant fluctuations in key financial metrics over the past three years, culminating in a notable recovery in the fiscal year ending March 2025.\n\nBreakdown:\nIn the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, a slight decrease from 4,178.18 crore in March 2024, but an increase from 3,654.82 crore in March 2023. The total operating income mirrored this trend, remaining stable at 4,118.16 crore in March 2025. The total expenditure, excluding depreciation, decreased to 3,653.67 crore from 4,055.20 crore in the previous year, contributing to a significant rise in operating profit (PBDIT) to 516.61 crore, compared to 157.01 crore in March 2024 and 384.06 crore in March 2023. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surg..."
      },
      {
        "title": "Why is Akums Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-akums-drugs-fallingrising-3687448",
        "imagepath": "",
        "date": "2025-11-11 00:27:55",
        "description": "As of 10-Nov, Akums Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 439.70, reflecting a decrease of Rs 14.75 or 3.25%. The stock has underperformed its sector by 4.3% today and has been on a consecutive downward trend for the last three days, with a total decline of 6.63% during this period. The stock has also touched an intraday low of Rs 436, indicating significant selling pressure. Over the past year, the stock has generated a return of -44.83%, which is considerably worse than the benchmark Sensex, which has gained 5.09%. Despite a low debt-to-equity ratio and an attractive valuation indicated by a price-to-book value of 2.3, the company has shown poor long-term growth, with net sales growing at only 6.10% annually over the last five years.\n\nBroader market context indicates that while the Sensex has shown a slight decline of 0.53% over the past week, Akums Drug..."
      },
      {
        "title": "Why is Akums Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-akums-drugs-fallingrising-3636402",
        "imagepath": "",
        "date": "2025-10-20 23:20:31",
        "description": "As of 20-Oct, Akums Drugs & Pharmaceuticals Ltd is experiencing a price increase, currently at 467.40, reflecting a rise of 6.75 or 1.47%. Today's performance indicates that the stock has outperformed its sector by 0.79% and has shown a trend reversal after two consecutive days of decline. However, despite this short-term gain, the stock has underperformed over the past month with a return of -1.93% compared to a 2.10% increase in the benchmark. The stock has also faced significant challenges over the past year, with a staggering decline of -48.58% while the benchmark has gained 3.86%. The company maintains a low debt-to-equity ratio and an attractive valuation with a price-to-book value of 2.4, alongside a notable increase in profits by 1362%, which may support the recent price movement.\n\nBroader market context shows that while Akums Drugs has seen a slight uptick in the short term, its long-term performan..."
      },
      {
        "title": "Is Akums Drugs technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-akums-drugs-technically-bullish-or-bearish-3613476",
        "imagepath": "",
        "date": "2025-10-13 08:08:29",
        "description": "As of 10 October 2025, the technical trend for Akums Drugs has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST being bearish, alongside daily moving averages indicating a bearish trend. However, the weekly and monthly RSI readings are bullish, suggesting some underlying strength. The Bollinger Bands and OBV are also mildly bearish on a weekly basis. Overall, while there are bullish signals from the RSI, the prevailing indicators lean towards a mildly bearish outlook...."
      }
    ],
    "total": 148,
    "sid": "10039335",
    "stock_news_url": "https://www.marketsmojo.com/news/akums-drugs-pharmaceuticals-10039335"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "17-Nov-2025",
      "details": "Earning call transcript",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "17-Nov-2025",
      "details": "JM Financial India Conference 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Monitoring Agency Report",
      "datetime": "14-Nov-2025",
      "details": "Monitoring Agency Report",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Akums Drugs Sees Revision in Market Evaluation Amidst Challenging Fundamentals

2025-11-28 10:05:12

Akums Drugs has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and market positioning. This adjustment highlights evolving perspectives on the company’s financial health, valuation, technical outlook, and overall quality within the Pharmaceuticals & Biotechnology sector.

Why is Akums Drugs falling/rising?

2025-11-25 01:51:32

Recent Price Movement and Market Performance

Akums Drugs has been on a losing streak, with the stock falling for five consecutive days and registering a weekly decline of 5.91%, significantly underperforming the Sensex, which remained almost flat with a marginal 0.06% gain over the same period. The stock is trading perilously close to its 52-week low, just 1.67% above the ₹407.4 mark, underscoring the persistent bearish sentiment among investors. Intraday activity further highlighted weakness, with the share price touching a low of ₹411.1, down 2.5% during the session, and a weighted average price indicating that most volume was transacted near these lower levels.

Technically, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-...

How has been the historical performance of Akums Drugs?

2025-11-17 23:27:20

Answer: The historical performance of Akums Drugs shows a significant recovery and growth in recent years, particularly in the fiscal year ending March 2025. Breakdown: In the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, slightly down from 4,178.18 crore in March 2024 but up from 3,654.82 crore in March 2023. The total operating income mirrored the net sales at 4,118.16 crore for March 2025. The company's total expenditure decreased to 3,653.67 crore in March 2025 from 4,055.20 crore in March 2024, contributing to an operating profit (PBDIT) of 516.61 crore, a substantial increase from 157.01 crore in the previous year. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surged to 343.78 crore compared to just 0.79 crore in the prior year. The consolidated net profit also reflected t...

Akums Drugs Faces Financial Challenges Amid Declining Performance Metrics and Rising Costs

2025-11-14 11:03:32

Akums Drugs & Pharmaceuticals has faced a decline in financial performance for the quarter ending September 2025, despite reporting a higher profit after tax for the nine-month period. Key indicators show rising interest expenses and a significant drop in quarterly PAT, raising concerns about operational efficiency and financial sustainability.

Akums Drugs Q2 FY26: Profit Plunges 37% as Margins Compress Under Rising Costs

2025-11-14 09:46:28

Akums Drugs & Pharmaceuticals Ltd., one of India's leading pharmaceutical contract development and manufacturing organisations, reported a disappointing second quarter for FY2026, with consolidated net profit declining 37.46% year-on-year to ₹40.78 crores from ₹65.21 crores in Q2 FY25. The quarter-on-quarter performance was equally concerning, with profits falling 35.76% from ₹63.48 crores in Q1 FY26. The sharp contraction in profitability comes despite relatively stable revenue, raising questions about operational efficiency and cost management at the ₹6,635 crore market capitalisation company.

How has been the historical performance of Akums Drugs?

2025-11-13 23:53:16

Answer: The historical performance of Akums Drugs shows significant fluctuations in key financial metrics over the past three years, culminating in a notable recovery in the fiscal year ending March 2025. Breakdown: In the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, a slight decrease from 4,178.18 crore in March 2024, but an increase from 3,654.82 crore in March 2023. The total operating income mirrored this trend, remaining stable at 4,118.16 crore in March 2025. The total expenditure, excluding depreciation, decreased to 3,653.67 crore from 4,055.20 crore in the previous year, contributing to a significant rise in operating profit (PBDIT) to 516.61 crore, compared to 157.01 crore in March 2024 and 384.06 crore in March 2023. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surg...

Why is Akums Drugs falling/rising?

2025-11-11 00:27:55

As of 10-Nov, Akums Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 439.70, reflecting a decrease of Rs 14.75 or 3.25%. The stock has underperformed its sector by 4.3% today and has been on a consecutive downward trend for the last three days, with a total decline of 6.63% during this period. The stock has also touched an intraday low of Rs 436, indicating significant selling pressure. Over the past year, the stock has generated a return of -44.83%, which is considerably worse than the benchmark Sensex, which has gained 5.09%. Despite a low debt-to-equity ratio and an attractive valuation indicated by a price-to-book value of 2.3, the company has shown poor long-term growth, with net sales growing at only 6.10% annually over the last five years. Broader market context indicates that while the Sensex has shown a slight decline of 0.53% over the past week, Akums Drug...

Why is Akums Drugs falling/rising?

2025-10-20 23:20:31

As of 20-Oct, Akums Drugs & Pharmaceuticals Ltd is experiencing a price increase, currently at 467.40, reflecting a rise of 6.75 or 1.47%. Today's performance indicates that the stock has outperformed its sector by 0.79% and has shown a trend reversal after two consecutive days of decline. However, despite this short-term gain, the stock has underperformed over the past month with a return of -1.93% compared to a 2.10% increase in the benchmark. The stock has also faced significant challenges over the past year, with a staggering decline of -48.58% while the benchmark has gained 3.86%. The company maintains a low debt-to-equity ratio and an attractive valuation with a price-to-book value of 2.4, alongside a notable increase in profits by 1362%, which may support the recent price movement. Broader market context shows that while Akums Drugs has seen a slight uptick in the short term, its long-term performan...

Is Akums Drugs technically bullish or bearish?

2025-10-13 08:08:29

As of 10 October 2025, the technical trend for Akums Drugs has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST being bearish, alongside daily moving averages indicating a bearish trend. However, the weekly and monthly RSI readings are bullish, suggesting some underlying strength. The Bollinger Bands and OBV are also mildly bearish on a weekly basis. Overall, while there are bullish signals from the RSI, the prevailing indicators lean towards a mildly bearish outlook....

View All News